← Research index · Disorder page · Source YAML

Cross-provider research synthesis

Osteosarcoma

MONDO:0009807 Curated 2026-07-04T00:00:00Z 9 harmonized findings

falcon · 19 citations asta · 20 citations perplexity · 60 citations

Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Osteosarcoma is the most common primary malignant bone tumor, arising from bone-forming mesenchymal cells, predominantly affecting children, adolescents, and young adults, and carrying a high propensity for lung metastasis, the main cause of death.

UNANIMOUS INTEGRATED

epidemiologyphenotype

Provider	Stance	Score	Evidence
asta	CONCORDANT	95%	Osteosarcoma is the most frequent malignant primary bone tumor characterized by a high potency to form lung metastases which is the main cause of death. Asta's top retrieved paper states the most-common-bone-tumor and lung-metastasis characterization directly. PMID:22448123
perplexity	CONCORDANT	95%	Osteosarcoma (OS) represents the most common primary malignant bone tumor affecting adolescents and young adults, characterized by rapid, aggressive growth and a high propensity for early metastatic dissemination Perplexity opens with the same epidemiologic and phenotypic framing.
falcon	CONCORDANT	85%	Osteosarcoma (OS) is a high-grade primary malignant bone tumor characterized by profound genomic instability, dysregulated developmental and stress-response signaling, metabolic rewiring, and a uniquely immunosuppressive bone tumor microenvironment (TME) that collectively drive invasion, lung metastasis, and treatment resistance Falcon confirms the high-grade primary bone tumor identity and lung metastasis, though its pathophysiology focus does not restate the age demographics.

Inactivation of the TP53 and RB1 tumor suppressor genes is the central genetic driver of osteosarcoma development.

UNANIMOUS INTEGRATED

genetic_factorpathophysiology

Provider	Stance	Score	Evidence
perplexity	CONCORDANT	95%	The molecular foundation of osteosarcoma development centers on the inactivation of two critical tumor suppressor genes, TP53 and RB1, which regulate fundamental cellular processes including DNA damage response, cell cycle progression, and apoptosis Perplexity makes TP53/RB1 inactivation the foundational genetic lesion, with mechanistic detail.
falcon	CONCORDANT	90%	frequent loss of key tumor suppressors (TP53, RB1, ATRX) and gains of oncogenes (MYC, MDM2) Falcon names TP53/RB1 (and ATRX) loss alongside MYC/MDM2 gains as defining lesions. DOI:10.3390/ijms241411367
asta	CONCORDANT	85%	several osteosarcoma-driving genes have been identified, such as TP53, RB1, and PTEN Asta's retrieved literature likewise identifies TP53 and RB1 among the core osteosarcoma-driving genes. PMID:36438897

Osteosarcoma is marked by extreme genomic instability, with catastrophic chromosomal rearrangement (chromothripsis) and kataegis as a defining feature rather than simple recurrent point mutations.

MAJORITY INTEGRATED

pathophysiologygenetic_factor

Provider	Stance	Score	Evidence
falcon	CONCORDANT	95%	Genomic catastrophe is a defining feature: chromothripsis and kataegis co-occur with frequent loss of key tumor suppressors Falcon foregrounds chromothripsis and kataegis as the defining genomic-catastrophe feature. DOI:10.3390/ijms241411367
perplexity	CONCORDANT	90%	Osteosarcoma represents one of the malignancies most profoundly driven by chromothripsis, which contributes significantly to profound genome complexity Perplexity independently emphasizes chromothripsis/chromoanagenesis and the structural-variant-dominated (rather than SNV-dominated) mutational landscape.
asta	PARTIAL	45%	The high heterogeneity and genetic complexity of OS make it challenging to identify new therapeutic targets Asta's retrieved snippets acknowledge the high genetic complexity/heterogeneity of osteosarcoma but do not specifically name chromothripsis or kataegis. PMID:34681692

Osteosarcoma arises from cells along the mesenchymal-osteogenic lineage (MSCs and/or osteoblast-committed progenitors) that acquire oncogenic lesions under the influence of bone microenvironment signals.

UNANIMOUS INTEGRATED

pathophysiologygenetic_factor

Provider	Stance	Score	Evidence
asta	CONCORDANT	85%	OS origin is attributed to several epigenetic and/or genetic alterations in mesenchymal stem cells (MSCs) or MSC-derived osteogenic lineages Asta's retrieved literature attributes OS origin to MSCs or MSC-derived osteogenic lineages. PMID:29200460
perplexity	CONCORDANT	90%	osteosarcoma development is initiated by different cell types along the mesenchymal-osteogenic lineage targeted with relevant oncogenic lesions, like inactivation of tumor suppressor genes P53 and RB, and becomes highly influenced by bone microenvironment signals Perplexity weighs the MSC vs osteoblast hypotheses and concludes the lineage-plus-microenvironment view.
falcon	CONCORDANT	75%	developmental osteoblast/MSC lineage acquires catastrophic structural lesions (chromothripsis/kataegis), with early loss of TP53/RB1/ATRX and focal oncogene gains (MYC/MDM2) Falcon places initiation in the osteoblast/MSC lineage acquiring the founding structural lesions.

The PI3K/AKT/mTOR signaling pathway is frequently hyperactivated in osteosarcoma and drives proliferation, survival, migration, and EMT.

UNANIMOUS INTEGRATED

pathophysiologytreatment

Provider	Stance	Score	Evidence
perplexity	CONCORDANT	95%	PI3K/AKT/mTOR signaling pathway represents one of the most important oncogenic pathways frequently hyperactivated in osteosarcoma Perplexity devotes a full section to PI3K/AKT/mTOR hyperactivation and its downstream effects.
falcon	CONCORDANT	80%	signal transduction via PI3K/AKT/mTOR Falcon lists PI3K/AKT/mTOR among the convergent pathways driving proliferation, survival, and EMT-like migration.
asta	CONCORDANT	80%	Accumulating evidence suggests that the PI3K/Akt pathway is involved in cancer initiation and progression, such as tumorigenesis, apoptosis inhibition, proliferation and drug resistance. Asta's retrieved literature affirms PI3K/Akt involvement in OS initiation, progression, and drug resistance. PMID:33994806

Epithelial-mesenchymal transition (EMT) is a key step enabling osteosarcoma invasion and metastatic dissemination.

UNANIMOUS INTEGRATED

pathophysiologyphenotype

Provider	Stance	Score	Evidence
perplexity	CONCORDANT	90%	The epithelial-mesenchymal transition (EMT) represents a vital step in osteosarcoma progression toward metastasis Perplexity treats EMT as a vital step toward metastasis and details its transcription-factor control.
asta	CONCORDANT	80%	EMT also plays a pivotal position in primary and secondary metastases in OS Asta's retrieved PDGFRβ paper affirms EMT's pivotal role in OS metastasis. PMID:32580247
falcon	CONCORDANT	80%	EMT-like programs, ECM remodeling, and chemotactic axes enable intravasation and lung colonization Falcon links EMT-like programs and ECM remodeling to intravasation and lung colonization.

Osteosarcoma has an immunosuppressive tumor microenvironment in which tumor-associated macrophages and other suppressive populations facilitate immune evasion, progression, and drug resistance.

MAJORITY INTEGRATED

pathophysiologytreatment

Provider	Stance	Score	Evidence
falcon	CONCORDANT	90%	expansion of immunoregulatory LAMP3+CCR7+CD83+ dendritic cells (mregDCs) and SPP1+ tumor-associated macrophages (TAMs) Falcon's single-cell synthesis details immune evasion via MHC-I/B2M loss, PD-L1/CD24, mregDCs, and SPP1+ TAMs. DOI:10.1038/s41413-022-00237-6
perplexity	CONCORDANT	90%	In osteosarcoma, TAMs may constitute over 50 percent of immune cells, significantly influencing tumor initiation, progression, metastasis, immunosuppression, and drug resistance Perplexity quantifies TAM dominance and covers the full suppressive milieu (Tregs, MDSCs, NK suppression).
asta	PARTIAL	50%	Macrophages are highly plastic and the inflammatory phenotype (M1) and antiinflammatory phenotype (M2) may play opposite roles in the progression of osteosarcoma. Asta's retrieved literature notes macrophage M1/M2 plasticity in OS progression but does not develop the broader immunosuppressive-evasion program. PMID:33994806

Standard treatment is multimodal: neoadjuvant and adjuvant multi-agent chemotherapy (methotrexate, doxorubicin, cisplatin; MAP) combined with surgical resection, with chemoresistance a major limitation.

MAJORITY INTEGRATED

treatment

Provider	Stance	Score	Evidence
asta	CONCORDANT	90%	Pre-operative and post-operative chemotherapy regimens, which include methotrexate, doxorubicin, and cisplatin (MAP), are designed to reduce tumor size before surgery and to eliminate any residual tumor cells afterward Asta's retrieved literature specifies the MAP regimen within the standard surgery-plus-chemotherapy plan. PMID:40283955
perplexity	CONCORDANT	85%	combining neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy Perplexity describes the same multimodal neoadjuvant-chemo/surgery/adjuvant-chemo backbone and devotes a section to chemoresistance mechanisms.
falcon	PARTIAL	45%	chemotherapy enriches stem-like tumor cells and CAF-driven ECM programs while depleting effectors, fostering resistance and recurrence Falcon addresses chemotherapy's microenvironmental remodeling and resistance but does not name the standard MAP regimen or the surgical backbone.

Prognosis is stage-dependent: roughly 60-70% five-year survival for localized disease versus only ~20-30% for metastatic disease.

UNANIMOUS INTEGRATED

prognosisepidemiology

Provider	Stance	Score	Evidence
perplexity	CONCORDANT	90%	the five-year survival rate for patients with localized disease remains approximately 65 percent, dropping dramatically to approximately 25 percent for those presenting with metastatic disease Perplexity gives the localized-vs-metastatic survival split explicitly.
asta	CONCORDANT	85%	five-year survival rate among OS patients has improved to 60%-75% [4]. However, 30%-40% of OS patients are associated with pulmonary metastasis and relapse, which have significantly poor prognosis, with an overall five-year survival rate of about 20% Asta's retrieved literature reports the same stage-dependent survival contrast. PMID:27058531
falcon	SILENT	—	Falcon's pathophysiology-focused report does not report five-year survival rates or stage-based prognostic figures.

Narrative

Overview

All three providers frame osteosarcoma as the most common primary malignant bone tumor of children, adolescents, and young adults, arising from the mesenchymal-osteogenic lineage and defined clinically by aggressive local growth and early hematogenous lung metastasis. Where they differ is in altitude and method: falcon reads as a mechanism-first synthesis anchored in 2023-2024 single-cell and genomics literature (genomic catastrophe, signaling convergence, immunosuppressive microenvironment); perplexity is a broad multi-domain narrative that walks from genetics through signaling, metabolism, cell of origin, tumor microenvironment, staging, clinical presentation, and chemoresistance; and asta is retrieval-only, surfacing verbatim snippets from the primary literature without a second-stage synthesis. Read together they triangulate a consistent picture in which a structural-variant-dominated genome, hijacked developmental signaling, and an immune-evasive bone niche drive a chemoresistant, metastasis-prone malignancy.

Agreement

Convergence is strong on the core pathophysiology. All three name TP53 and RB1 inactivation as the central genetic drivers, place the cell of origin along the mesenchymal-osteogenic lineage under bone-microenvironment influence, implicate PI3K/AKT/mTOR signaling in proliferation and survival, and treat EMT as a key step toward invasion and lung metastasis. falcon and perplexity independently foreground chromothripsis/genomic instability and an immunosuppressive tumor microenvironment; asta corroborates the surrounding facts (most-common bone tumor, MSC/osteogenic origin, PI3K/Akt involvement, macrophage plasticity, stage-dependent survival) from independent primary sources. asta and perplexity agree closely on the multimodal standard of care and on the localized-versus-metastatic survival split.

Divergence

Divergence is coverage-driven rather than contradictory; no direct conflicts were found. falcon contributes the richest single-cell microenvironment detail (mregDCs, SPP1+ TAMs, MHC-I/B2M loss, PD-L1/CD24 evasion, post-chemotherapy remodeling) but is silent on five-year survival figures and does not name the standard MAP regimen. perplexity is uniquely comprehensive on genetics beyond TP53/RB1 (MDM2, MYC/CCNE1, ATRX, chromoanagenesis), on additional pathways (Wnt/beta-catenin-RUNX2, HIF-1alpha, VEGF/angiogenesis), on metabolic reprogramming (Warburg, glutamine/GLS-1 dependency), and on clinical staging, presentation, and chemoresistance mechanisms. asta, being snippet-only, supports genomic complexity and macrophage M1/M2 plasticity only partially and lacks the chromothripsis and full immune-evasion detail the other two supply, but it adds the concrete standard-of-care MAP regimen and cell-death-pathway leads (ferroptosis, necroptosis, autophagy) the others underplay.

Integration

High-confidence, multi-provider claims are strong candidates for promotion into the disorder YAML: TP53/RB1 tumor-suppressor inactivation as the founding lesion; structural-variant/chromothripsis-driven genomic instability; the mesenchymal-osteogenic cell of origin shaped by bone-niche signals; PI3K/AKT/mTOR hyperactivation; EMT-driven lung metastasis; the immunosuppressive TAM-rich microenvironment; the multimodal MAP-chemotherapy plus surgery standard of care; and the stage-dependent prognosis (~60-70% localized vs ~20-30% metastatic five-year survival). These are already tagged INTEGRATED in the findings above.

Not integrated (leads)

Several single-provider mechanistic leads are worth retaining but were not promoted here pending independent verification against primary abstracts: perplexity's specific TP53 fusion partners and percentages, MYC/CCNE1 coamplification, HIF-1alpha/VEGF angiogenic and metabolic (glutamine/GLS-1, Warburg) axes, and the extensive miRNA/lncRNA regulatory nodes; and asta's alternative regulated-cell-death vulnerabilities (ferroptosis, necroptosis via RIPK/MLKL, PERK-mediated autophagy). These remain research leads rather than curated content because they rest on a single report and, in asta's case, on retrieval snippets without synthesis.

Cross-provider synthesis for Osteosarcoma comparing three independent deep-research reports: falcon (pathophysiology-focused, single-cell/genomics oriented), asta (retrieval-only literature snippets, no synthesis stage), and perplexity (comprehensive multi-domain narrative). The three converge strongly on the core pathophysiology (TP53/RB1 inactivation, genomic instability/chromothripsis, mesenchymal-osteogenic cell of origin, PI3K/AKT/mTOR signaling, EMT-driven lung metastasis, immunosuppressive TME). Divergence is coverage-driven rather than contradictory: falcon is silent on clinical prognosis/survival and does not name the standard MAP regimen; asta (snippet-only) supports genomic complexity and TAM plasticity only partially, lacking the chromothripsis and full immune-evasion detail the other two provide. No direct contradictions were found. best_matching_text values are verbatim excerpts from the cited report files; per-provider citations reflect the source each report leaned on and were not independently fetch-verified here.